Gene M. Koop, D.D.S.; Decision and Order
Published Date: 7/28/2026
Notice
Summary
No summary available.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked
The Drug Enforcement Administration revoked Gene M. Koop, D.D.S.'s DEA Certificate of Registration No. BK1369633, because his Oklahoma dentistry license expired on December 31, 2023 and his OBNDD registration expired on October 31, 2024. The revocation takes effect August 27, 2026 and ends his authority under that DEA registration to prescribe, administer, or dispense controlled substances.
Pending Renewal and New Applications Denied
DEA denied any pending applications by Gene M. Koop, D.D.S., to renew or modify Certificate No. BK1369633 and denied any other pending application for additional registration in Oklahoma. That denial is part of the Order effective August 27, 2026.
Opportunity to Seek Reconsideration
The Order allows Gene M. Koop, D.D.S., to file a properly supported motion for reconsideration of the factual findings within fifteen calendar days of the date of the Order. Any such motion and responses must be filed and served by email to the other party and to the DEA Office of the Administrator.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-15199, Kerri Zavota, DVM; Decision and Order
2026-14286, Importer of Controlled Substances Application: Catalent Greenville, Inc.
Catalent Greenville, Inc. wants to become an official importer of some powerful controlled substances, including LSD and related drugs. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 17, 2026. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
2026-14135, David Enright, M.D.; Decision and Order
Dr. David Enright from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-14137, Shane Lydon, M.D.; Decision and Order
Dr. Shane Lydon's license to handle controlled substances in Maine has been revoked because he lost his state authority and didn’t ask for a hearing. This means he can no longer prescribe or manage these drugs, effective immediately. Anyone relying on his registration should update their records and note this change to avoid legal trouble.